Abstract: The invention provides a peptide or a pharmaceutical salt thereof having a length from 14 to 50 and comprising a sequence having at least a 85% of sequence identity with respect to SEQ ID NO: 1, wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; the C-terminal end corresponds to —C(O)R4; and N-terminal end corresponds to —NHR5; the peptide optionally comprising a linker biradical “L” of formula (I) connecting an alpha carbon atom of an amino acid located at position “i” with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence SEQ ID NO: 1. The present invention also provides fusion proteins and pharmaceutical compositions comprising the peptides of the invention as well as their use in therapy and, particularly, in the treatment of a disease caused by an increase or reduction in VEGF levels.

Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.

Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.

Abstract: An apparatus is provided comprising a first acquisition unit for acquiring a data set including a plurality of types of measurement data indicating a state of an object, a supplying unit for supplying, in response to the data set being input, the data set acquired by the first acquisition unit to a model that outputs a state indication value indicating classification of a state of the object, a first identification unit for identifying, when one of the state indication value is output from the model in response to one of the data set being supplied, at least one type of measurement data, among the plurality of types of measurement data, having a larger influence on the one state indication value than a reference, based on the one data set, and a display control unit for displaying the one state indication value and the at least one type of measurement data.

Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTB VAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.

Abstract: One embodiment of the present invention provides a switch. The switch includes a storage device, a processing module, and a database module. The storage device can maintain a database storing configuration information for the switch. During operation, the processing module produces a piece of data associated with operations of the switch based on the configuration information. The database module then stores the piece of data in a database table of the database without caching the piece of data in a memory of the switch after the piece of data is stored in the database. In this way, the database module can reduce the memory occupancy of the processing module in comparison with the storage occupancy of a schema corresponding to the database table. Subsequently, the processing module can program a hardware module of the switch with the piece of data prior to receiving an acknowledgment from the database module.

Abstract: In the present invention a methodology has been identified for the detection of MGMT methylation in blood, serum or plasma of a human subject with high sensitivity and specificity, surpassing the techniques described so far. This methodology will allow the diagnosis and monitoring of those patients diagnosed with glioblastomas using a non-invasive method. This invention could be extended to other tumor types in which methylation of the MGMT gene was also present as a tumor marker.

Abstract: The present invention responds to the need to provide an endogenous miRNA for quantifying the amount of one or more targets miRNA in exosomes using normalization, that that does not vary within the different tumor types and within the different chemotherapeutic treatments. This is essential to be able to perform robust analysis of the expression of exosomal miRNAs in these pathologies. So far, other types of endogenous controls have been used that are not strictly exosomal, thus reducing their reliability as normalizers. Therefore, for the first time, an endogenous control specific for the exosomal compartment would be available.

Abstract: One embodiment of the present invention provides a switch. The switch includes a storage device, a processing module, and a database module. The storage device can maintain a database storing configuration information for the switch. During operation, the processing module produces a piece of data associated with operations of the switch based on the configuration information. The database module then stores the piece of data in a database table of the database without caching the piece of data in a memory of the switch after the piece of data is stored in the database. In this way, the database module can reduce the memory occupancy of the processing module in comparison with the storage occupancy of a schema corresponding to the database table. Subsequently, the processing module can program a hardware module of the switch with the piece of data prior to receiving an acknowledgment from the database module.

Abstract: The present disclosure relates to a process for the hydrodeoxygenation of vegetable oils or animal fats to produce green diesel, which comprises contacting the vegetable oil or animal fat with a Nickel-Molybdenum or Cobalt-Molybdenum catalyst supported on alumina-titania or titania, respectively; in a fixed bed reactor in the presence of hydrogen. The process involves hydrocracking, hydrogenation, decarboxylation, decarbonylation, carried out in a fixed bed reactor at temperature of about 270° C. to about 360° C., pressure of about 40 kgf/cm2 to about 60 kgf/cm2, liquid hourly space velocity (LHSV) between about 0.8 h?1 to about 3.0 h?1, and H2/oil ratio of about 2,700 ft3/bbl to about 7,000 ft3/bbl, that allows to obtain a conversion up to 99% and up to 92.7% yield on green diesel.

Abstract: The present invention relates to a method of enhancing the activity of a transcription factor in a plant comprising expressing in said plant a chimeric protein comprising a GIF moiety comprising a GIF domain or fragment thereof, and a DNA binding domain (DBD) moiety. The chimeric proteins comprise a GIF moiety comprising a GIF domain or fragment thereof, or a polypeptide with an amino acid sequence having at least 85%, preferably at least 90%, even more preferably at least 95% sequence identity to the amino acid sequence of a GIF domain or fragment thereof; and a DBD moiety comprising the DBD or plant transcription factor whose activity enhancement is intended, or a binding protein which is capable of forming a tertiary complex with the DBD or transcription factor whose activity modification and/or enhancement is intended. The invention also relates to polynucleotides and polypeptides useful in the method of the invention.

Abstract: The present disclosure relates to a process for the hydrodeoxygenation of vegetable oils or animal fats to produce green diesel, which comprises contacting the vegetable oil or animal fat with a Nickel-Molybdenum or Cobalt-Molybdenum catalyst supported on alumina-titania or titania, respectively; in a fixed bed reactor in the presence of hydrogen. The process involves hydrocracking, hydrogenation, decarboxylation, decarbonylation, carried out in a fixed bed reactor at temperature of about 270° C. to about 360° C., pressure of about 40 kgf/cm2 to about 60 kgf/cm2, liquid hourly space velocity (LHSV) between about 0.8 h?1 to about 3.0 h?1, and H2/oil ratio of about 2,700 ft3/bbl to about 7,000 ft3/bbl, that allows to obtain a conversion up to 99% and up to 92.7% yield on green diesel.

Abstract: A percussive instrument mallet includes a molded head, a shaft having an optionally threaded nose, and a rigid insert fixed completely within the head. The insert has an inner profile including threads or other protrusions that mate with the nose of the shaft, and an outer profile that is embedded in the mold material. An outer portion of the insert includes a weighting ring that is also embedded in the mold material. The method includes selecting a tool with an optionally threaded nose and a central bore, threading or otherwise securing an insert onto the nose of the tool, supporting a weight ring on the insert; placing the threaded insert and weight ring in a mold, molding the head while over-molding the weight ring and insert, drawing air out of the head through the central bore, disengaging the tool from the insert, and attaching a mallet shaft into the insert.

Abstract: The present invention relates to the production of biodiesel and alkyl esters by the transesterification of triglyceride esters, with alcohols in heterogeneous phase in the presence of heterogeneous catalysts, with yields higher than 80%, at a temperature from 0 to 300° C., residence time from 20 minutes to 20 h, space velocity of 0.1 to 10 h?1, pressure of 25-100 kg/cm2 (24.5-98.07 bar), methanol/oil molar ratio of 10 to 40 and catalyst concentration of 0.001 to 20 weight % based on tri-, di- or monoglyceride. The method produces biodiesel and alkyl esters by transesterification of tri-, di- or mono-glycerides, from palm, jatropha, castor, soybean and sunflower oils, wherein the alcohoxyls R1O, R2O and R3O of the glycerides are C1 to C24 and a C1-C4 alcohol, such as methanol, in an alcohol:oil ratio from 3:1 to 50:1.

Abstract: The present invention relates to heterogeneous acid catalysts comprising or consisting of mixed metal salts, of lithium and aluminum phosphates and sulfates, and combinations with metallic cations, such as magnesium, titanium, zinc, zirconium and gallium, to provide adequate Lewis acidity; organic or inorganic porosity promoters, such as polysaccharides; and agglomerates, such as clays, kaolin and metal oxides of the type MxOy, where; M=Al, Mg, Sr, Zr or Ti, and other metals of groups IA, IIA and IVB, x=1 or 2 and y=2 or 3, for the formation of particles. A process is disclosed for obtaining from the catalyst by the hydrolysis of aluminum lithium hydride with water and oxygenated solvent, such as an ether. The catalysts are used in batch reactor and continuous flow systems in reactions that require moderate Lewis acidity, such as refining, petrochemical and general chemistry, including the transesterification of glycerides to produce alkyl esters.

Abstract: The present invention relates to a method of enhancing the activity of a transcription factor in a plant comprising expressing in said plant a chimeric protein comprising a GIF moiety comprising a GIF domain or fragment thereof, and a DNA binding domain (DBD) moiety. The chimeric proteins comprise a GIF moiety comprising a GIF domain or fragment thereof, or a polypeptide with an amino acid sequence having at least 85%, preferably at least 90%, even more preferably at least 95% sequence identity to the amino acid sequence of a GIF domain or fragment thereof; and a DBD moiety comprising the DBD or plant transcription factor whose activity enhancement is intended, or a binding protein which is capable of forming a tertiary complex with the DBD or transcription factor whose activity modification and/or enhancement is intended. The invention also relates to polynucleotides and polypeptides useful in the method of the invention.

Abstract: The present invention relates to heterogeneous acid catalysts comprising or consisting of mixed metal salts, of lithium and aluminum phosphates and sulfates, and combinations with metallic cations, such as magnesium, titanium, zinc, zirconium and gallium, to provide adequate Lewis acidity; organic or inorganic porosity promoters, such as polysaccharides; and agglomerates, such as clays, kaolin and metal oxides of the type MxOy, where; M=Al, Mg, Sr, Zr or Ti, and other metals of groups IA, IIA and IVB, x=1 or 2 and y=2 or 3, for the formation of particles. A process is disclosed for obtaining from the catalyst by the hydrolysis of aluminum lithium hydride with water and oxygenated solvent, such as an ether. The catalysts are used in batch reactor and continuous flow systems in reactions that require moderate Lewis acidity, such as refining, petrochemical and general chemistry, including the transesterification of glycerides to produce alkyl esters.

Abstract: The present invention relates to the production of biodiesel and alkyl esters by the transesterification of triglyceride esters, with alcohols in heterogeneous phase in the presence of heterogeneous catalysts, with yields higher than 80%, at a temperature from 0 to 300° C., residence time from 20 minutes to 20 h, space velocity of 0.1 to 10 h?1, pressure of 25-100 kg/cm2 (24.5-98.07 bar), methanol/oil molar ratio of 10 to 40 and catalyst concentration of 0.001 to 20 weight % based on tri-, di- or monoglyceride. The method produces biodiesel and alkyl esters by transesterification of tri-, di- or mono-glycerides, from palm, jatropha, castor, soybean and sunflower oils, wherein the alcohoxyls R1O, R2O and R3O of the glycerides are C1 to C24 and a C1-C4 alcohol, such as methanol, in an alcohol:oil ratio from 3:1 to 50:1.

Abstract: Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses contain sequences which are inserted at an MVA insertion site and enable simultaneous expression of antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. These viruses are stable and can trigger immune responses against a large variety of antigens. Viruses having a chimeric protein from HIV-1 are suitable for the preparation of vaccines against AIDS.

Abstract: Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses object of the invention contain sequences which are inserted at the same MVA insertion site and which enable the simultaneous expression of various antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. Said viruses are stable and can trigger immune responses against a large variety of antigens.